Nano-X Imaging Ltd.
Nano-X Imaging (NNOX) expanded its U.S. distribution for Nanox.ARC, a 3D imaging system, via a deal with Associated X-Ray Imaging. The agreement aims to boost access in New England and supports Nanox's U.S. commercial strategy. NNOX shares are up 1.02% in premarket trading at $0.72.
Nano-X Imaging (NNOX) reported Q1 2026 revenue of $4.3M, up from $2.8M year-over-year. The company's growth is driven by its end-to-end imaging platform, FDA-cleared AI solutions, and partnerships with major healthcare organizations like RadNet and Cedars-Sinai.
Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.
Over the past 7 days, alphai's AI scored 1 news story mentioning NNOX (Nano-X Imaging Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NNOX coverage spans technology, insider activity and earnings.
In the last 30 days, NNOX insiders filed 1 SEC Form 4 transaction — 1 purchase ($10K) and no sales. The most active reporter was Meltzer Erez, Chief Executive Officer, with 1 filing.
Potential modest boost to US sales as the partnership expands regional access.
Small revenue increase may modestly boost price; market likely already priced expectations.
The deal is a UK go-to-market expansion that could support HealthOST adoption and recurring license revenue, but it is not quantified in the release.
The update is primarily a funding and project-execution catalyst, potentially reducing near-term dilution risk while supporting commercialization timelines.
This is an insider buy, but the filing does not disclose new company fundamentals beyond the transaction itself.
alphai scores every news story that mentions NNOX with an AI model for sentiment and relevance, and aggregates insider trades from Nano-X Imaging Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nano-X Imaging (NNOX) expanded its U.S. distribution for Nanox.ARC, a 3D imaging system, via a deal with Associated X-Ray Imaging. The agreement aims to boost access in New England and supports Nanox's U.S. commercial strategy. NNOX shares are up 1.02% in premarket trading at $0.72.
1 min readNano-X Imaging (NNOX) reported Q1 2026 revenue of $4.3M, up from $2.8M year-over-year. The company's growth is driven by its end-to-end imaging platform, FDA-cleared AI solutions, and partnerships with major healthcare organizations like RadNet and Cedars-Sinai.
1 min readNanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.
4 min readNano One Materials Corp. reported Q2 2026 net assets of $18.2 million, working capital of $17.6 million, and cash of $19.3 million. It said it secured over $63 million in non-dilutive funding since 2024, including $12.3 million in H1 2026 and $1.0 million from Natural Resources Canada in July. Candiac expansion engineering was 85% complete, on schedule for first half 2027.
6 min readSuesskind Dan S purchased 50,000 shares of Nano-X Imaging Ltd. (NNOX) at an average of $0.93 ($0.92–$0.94) across 2 trades on 2026-07-27.
1 min readKainan Noga purchased 33,000 shares of Nano-X Imaging Ltd. (NNOX) at $0.90 on 2026-07-28.
1 min readMeltzer Erez (Chief Executive Officer) purchased 36,000 indirectly-held shares of Nano-X Imaging Ltd. (NNOX) at $0.93 on 2026-07-27.
1 min readNanox Imaging Ltd. (NASDAQ: NNOX) said clinical study data on its Nanox.AI FDA-cleared cardiac AI solution (HealthCCSng) will be presented at SCCT 2026. The AI INFORM trial and a multi-site analysis will report agreement between AI-detected coronary artery calcium and expert assessment, according to abstracts from Brigham and Women’s Hospital and others.
3 min readNano One Materials Corp. said it and alliance partner Worley Chemetics have completed a “One-Pot” lithium iron phosphate (LFP) cathode active material package, using qualified equipment vendors in North America, Europe and South Africa, meeting a Class 3 cost estimate and targeting first-half 2026 marketing. The package bundles a technology license, process design and qualified equipment; a hybrid configuration for H2 2026 adds optional Chinese sourcing for non-IP-sensitive equipment.
4 min readNanox Imaging (NASDAQ: NNOX) said it signed an exclusive distribution agreement with Top Med SAC for Peru to deploy the Nanox.ARC system and related services. Top Med will handle regulatory approvals, marketing, installation, maintenance, training and support. The deal is a capex model with an initial expected deployment of six systems, subject to permits.
3 min read
